oral glp 1 agonist GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is In a major milestone for
Description
These results established tirzepatide as the most potent agent in the current pharmacologic armamentarium for obesity
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
In clinical trials, these drugs have helped participants lose an average of 15% of their weight over a year
Third-party tested by Eurofins for potency and purity
Expanded Indications for GLP-1 Receptor Agonists The 2025 American Diabetes Association (ADA) Standards of Care have broadened the use of GLP-1 receptor agonists beyond glycemic control
This reduces the glycemic load, and improves the pancreatic b-cell insulin secretion, it increases HDL-C and further decreases serum triglycerides and glucose [6]
